|
JPH0487425A
(ja)
*
|
1990-07-31 |
1992-03-19 |
Fujitsu Ltd |
回線切り替え装置
|
|
KR100926247B1
(ko)
*
|
2001-02-24 |
2009-11-12 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
PL1712547T3
(pl)
*
|
2004-02-05 |
2012-04-30 |
Kyorin Seiyaku Kk |
Pochodna bicykloestrowa
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
TW200534879A
(en)
*
|
2004-03-25 |
2005-11-01 |
Bristol Myers Squibb Co |
Coated tablet formulation and method
|
|
US7829720B2
(en)
|
2004-05-04 |
2010-11-09 |
Bristol-Myers Squibb Company |
Process for preparing atazanavir bisulfate and novel forms
|
|
US20050256314A1
(en)
*
|
2004-05-04 |
2005-11-17 |
Soojin Kim |
Process employing controlled crystallization in forming crystals of a pharmaceutical
|
|
TWI354569B
(en)
|
2004-05-28 |
2011-12-21 |
Bristol Myers Squibb Co |
Coated tablet formulation and method
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
GB0526291D0
(en)
*
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
|
DE602006013781D1
(de)
*
|
2006-02-09 |
2010-06-02 |
Teva Pharma |
Stabile pharmazeutische Zubereitungen von Montelukast-Natrium
|
|
EP1995237A4
(en)
*
|
2006-03-08 |
2011-07-06 |
Kyorin Seiyaku Kk |
PROCESS FOR PREPARING AN AMINOACETYLPYRROLIDINCARBONITRILE DERIVATIVE AND PRODUCTION PRODUCT THEREOF
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
KR101452915B1
(ko)
|
2006-05-04 |
2014-10-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
다형태
|
|
EP1852108A1
(en)
*
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
|
AR065809A1
(es)
|
2007-03-22 |
2009-07-01 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
|
US8143427B2
(en)
*
|
2007-03-22 |
2012-03-27 |
Kyorin Pharmaceutical Co., Ltd. |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative
|
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
|
EP2178512B1
(en)
*
|
2007-06-22 |
2011-03-09 |
Bristol-Myers Squibb Company |
Tableted compositions containing atazanavir
|
|
DK2170292T3
(da)
*
|
2007-06-22 |
2014-04-07 |
Bristol Myers Squibb Holdings Ireland |
Atazanavirholdige sammensætninger i tabletform
|
|
ES2360336T3
(es)
*
|
2007-06-22 |
2011-06-03 |
Bristol-Myers Squibb Company |
Composiciones en comprimidos que contienen atazanavir.
|
|
SI2178513T1
(sl)
*
|
2007-06-22 |
2011-05-31 |
Bristol Myers Squibb Co |
Tabletni sestavki vsebujoäśi atazanavir
|
|
EP2175740B1
(en)
*
|
2007-07-31 |
2018-06-06 |
Cargill, Incorporated |
Direct compressible dextrose
|
|
WO2010019279A1
(en)
*
|
2008-08-12 |
2010-02-18 |
Abuse Deterrent Pharmaceutical Llc |
Pharmaceutical compositions configured to deter dosage form splitting
|
|
AU2008286914B2
(en)
*
|
2007-08-13 |
2014-10-02 |
Ohemo Life Sciences Inc. |
Abuse resistant drugs, method of use and method of making
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
IT1393244B1
(it)
*
|
2008-07-18 |
2012-04-12 |
Universita' Degli Studi Di Milano |
Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
CA2732984A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Kyorin Pharmaceutical Co., Ltd. |
Process for production of bicyclo[2.2.2]octylamine derivative
|
|
CN102186474A
(zh)
*
|
2008-08-14 |
2011-09-14 |
杏林制药株式会社 |
稳定的医药组合物
|
|
UA119131C2
(uk)
|
2008-08-15 |
2019-05-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Похідні пурину для застосування при лікуванні пов'язаних із fab захворювань
|
|
CA2736421A1
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
JP2012512848A
(ja)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
有機化合物の塩の形態
|
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
|
EP2395988A2
(en)
|
2009-02-13 |
2011-12-21 |
Boehringer Ingelheim International GmbH |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
|
BRPI1008560B1
(pt)
|
2009-02-13 |
2021-08-31 |
Boehringer Ingelheim International Gmbh |
Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
|
|
SG174504A1
(en)
|
2009-03-27 |
2011-10-28 |
Bristol Myers Squibb Co |
Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
|
|
CN102438617A
(zh)
|
2009-03-27 |
2012-05-02 |
杏林制药株式会社 |
含有碱性添加剂的基质型缓释制剂
|
|
AU2010233718B2
(en)
|
2009-04-09 |
2015-11-05 |
Sandoz Ag |
Crystal forms of Saxagliptin
|
|
EP3315124B1
(en)
|
2009-11-13 |
2021-01-06 |
Astrazeneca AB |
Bilayer tablet formulations
|
|
JP5784623B2
(ja)
*
|
2009-11-13 |
2015-09-24 |
アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ |
速放性錠剤製剤
|
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
|
JP2013522279A
(ja)
|
2010-03-18 |
2013-06-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
|
|
CN102210693B
(zh)
*
|
2010-04-10 |
2013-10-09 |
山东新华制药股份有限公司 |
一种阿司匹林和双嘧达莫多层片的制备方法
|
|
US8501960B2
(en)
|
2010-05-05 |
2013-08-06 |
Assia Chemical Industries Ltd. |
Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
|
|
CA3070513C
(en)
|
2010-05-05 |
2023-01-03 |
Boehringer Ingelheim International Gmbh |
A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
|
|
KR20130093012A
(ko)
|
2010-06-24 |
2013-08-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
|
EP2601175A1
(en)
|
2010-08-06 |
2013-06-12 |
Sandoz AG |
A novel crystalline compound comprising saxagliptin and phosphoric acid
|
|
WO2012017029A1
(en)
|
2010-08-06 |
2012-02-09 |
Sandoz Ag |
Novel salts of saxagrliptin with organic di-acids
|
|
CN103370064A
(zh)
|
2010-09-03 |
2013-10-23 |
百时美施贵宝公司 |
使用水溶性抗氧化剂的药物制剂
|
|
EP2608788A1
(en)
|
2010-10-04 |
2013-07-03 |
Assia Chemical Industries Ltd. |
Polymorphs of saxagliptin hydrochloride and processes for preparing them
|
|
PL3400944T3
(pl)
|
2010-11-04 |
2020-11-16 |
Albireo Ab |
Inhibitory ibat w leczeniu chorób wątroby
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
CN102086172A
(zh)
*
|
2011-01-13 |
2011-06-08 |
廖国超 |
沙格列汀的药用盐及其制备方法
|
|
CA2826391C
(en)
*
|
2011-02-01 |
2017-01-24 |
Bristol-Myers Squibb Company |
Pharmaceutical formulations including an amine compound
|
|
DK2731947T3
(en)
|
2011-07-15 |
2019-04-23 |
Boehringer Ingelheim Int |
SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
|
|
AR089645A1
(es)
|
2011-08-12 |
2014-09-10 |
Boehringer Ingelheim Vetmed |
Particula multicapas de sabor enmascarado, metodo, uso, composicion farmaceutica
|
|
EA201490556A1
(ru)
|
2011-09-07 |
2014-08-29 |
Сановел Илач Санайи Ве Тиджарет Аноним Ширкети |
Составы ингибитора дпп-4
|
|
US9446000B2
(en)
|
2011-09-08 |
2016-09-20 |
Masdar Institute Of Science And Technology |
Cellulosic gel material as a pharmaceutical excipient
|
|
EP2578208B1
(en)
|
2011-10-06 |
2014-05-21 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
DPP-IV inhibitor solid dosage formulations
|
|
US20130189358A1
(en)
|
2012-01-10 |
2013-07-25 |
Roey Solomonovich |
Saxagliptin pharmaceutical formulations
|
|
WO2013130785A2
(en)
|
2012-03-01 |
2013-09-06 |
Bristol-Myers Squibb Company |
Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
CA2872542A1
(en)
|
2012-05-07 |
2013-11-14 |
Bayer Pharma Aktiengesellschaft |
Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
|
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
|
WO2013171166A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
WO2013179307A2
(en)
*
|
2012-05-29 |
2013-12-05 |
Mylan Laboratories Limited |
Stabilized pharmaceutical compositions of saxagliptin
|
|
WO2014030051A1
(en)
|
2012-08-23 |
2014-02-27 |
Aurobindo Pharma Limited |
Stable pharmaceutical compositions comprising saxagliptin
|
|
JP6283316B2
(ja)
*
|
2012-10-26 |
2018-02-21 |
株式会社三和化学研究所 |
アナグリプチン含有固形製剤
|
|
WO2014096982A1
(en)
|
2012-12-21 |
2014-06-26 |
Wockhardt Limited |
Stable pharmaceutical compositions of saxagliptin or salts thereof
|
|
WO2014096983A1
(en)
|
2012-12-21 |
2014-06-26 |
Wockhardt Limited |
Stable pharmaceutical compositions of saxagliptin or salts thereof
|
|
WO2014146093A2
(en)
|
2013-03-15 |
2014-09-18 |
Inspirion Delivery Technologies, Llc |
Abuse deterrent compositions and methods of use
|
|
WO2014193528A1
(en)
*
|
2013-04-29 |
2014-12-04 |
Anovel Pharmaceuticals, Llc |
Amorphous dosage forms and methods
|
|
CN103316056B
(zh)
*
|
2013-06-24 |
2015-07-08 |
江苏鹏鹞药业有限公司 |
一种板蓝根包衣分散片及其制备方法
|
|
WO2015071889A1
(en)
|
2013-11-18 |
2015-05-21 |
Ranbaxy Laboratories Limited |
Oral compositions of saxagliptin
|
|
WO2015071887A1
(en)
|
2013-11-18 |
2015-05-21 |
Ranbaxy Laboratories Limited |
Oral pharmaceutical compositions of saxagliptin
|
|
RU2686183C2
(ru)
*
|
2014-01-21 |
2019-04-24 |
БиПиЭсАй ХОЛДИНГЗ, ЭлЭлСи |
Пленочные покрытия быстрого высвобождения, содержащие среднецепочечные глицериды, и покрытые ими субстраты
|
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
|
CA2952406A1
(en)
|
2014-06-25 |
2015-12-30 |
Ea Pharma Co., Ltd. |
Solid formulation and method for preventing or reducing coloration thereof
|
|
US10729685B2
(en)
|
2014-09-15 |
2020-08-04 |
Ohemo Life Sciences Inc. |
Orally administrable compositions and methods of deterring abuse by intranasal administration
|
|
CN105520913B
(zh)
*
|
2014-09-28 |
2020-06-23 |
石药集团中奇制药技术（石家庄）有限公司 |
一种包含沙格列汀的微丸、其用途及其制备方法
|
|
CN105497023B
(zh)
*
|
2014-10-15 |
2021-05-25 |
北京福元医药股份有限公司 |
一种沙格列汀药物制剂
|
|
EP3012252A1
(en)
|
2014-10-24 |
2016-04-27 |
Ferring BV |
Crystal modifications of elobixibat
|
|
CN104557943B
(zh)
*
|
2014-12-23 |
2017-05-03 |
扬子江药业集团四川海蓉药业有限公司 |
一种维格列汀杂质的制备方法
|
|
CN105796503B
(zh)
*
|
2014-12-30 |
2019-05-07 |
深圳翰宇药业股份有限公司 |
一种沙格列汀微丸及其制剂
|
|
CN104672243B
(zh)
*
|
2015-02-10 |
2017-09-22 |
华润赛科药业有限责任公司 |
维格列汀降解杂质的制备方法
|
|
DK3277278T3
(da)
|
2015-04-02 |
2020-04-06 |
Theravance Biopharma R&D Ip Llc |
Kombinationsdoseringsform af en my-opioid receptorantagonist og et opioid
|
|
CN106176661B
(zh)
*
|
2015-04-29 |
2019-02-01 |
四川科伦药物研究院有限公司 |
一种沙格列汀或其盐的胶囊及其制备方法
|
|
CA2987912C
(en)
*
|
2015-06-30 |
2023-01-24 |
Genentech, Inc. |
Immediate-release tablets containing a drug and processes for forming the tablets
|
|
CN106924207A
(zh)
*
|
2015-12-31 |
2017-07-07 |
深圳翰宇药业股份有限公司 |
一种维格列汀片剂及其制备方法
|
|
US10786529B2
(en)
|
2016-02-09 |
2020-09-29 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US10441605B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US10441604B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
|
EP4233840A3
(en)
|
2016-06-10 |
2023-10-18 |
Boehringer Ingelheim International GmbH |
Combinations of linagliptin and metformin
|
|
JP2020530448A
(ja)
|
2017-08-09 |
2020-10-22 |
アルビレオ・アクチボラグ |
コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
|
|
CN108822820B
(zh)
*
|
2018-05-22 |
2020-11-03 |
东莞理工学院 |
一种隔离型水合物动力学抑制胶囊及其制备方法与应用
|
|
ES2942443T3
(es)
|
2018-06-05 |
2023-06-01 |
Albireo Ab |
Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
|
|
US10793534B2
(en)
|
2018-06-05 |
2020-10-06 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
BR112020024479A2
(pt)
|
2018-06-20 |
2021-03-02 |
Albireo Ab |
hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica
|
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
WO2020098904A1
(en)
|
2018-11-12 |
2020-05-22 |
Pharmaceutical Oriented Services Ltd |
Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor
|
|
US10975045B2
(en)
|
2019-02-06 |
2021-04-13 |
Aibireo AB |
Benzothiazepine compounds and their use as bile acid modulators
|
|
HUE060905T2
(hu)
|
2019-02-06 |
2023-04-28 |
Albireo Ab |
Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként
|
|
US10941127B2
(en)
|
2019-02-06 |
2021-03-09 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
CN109999006A
(zh)
*
|
2019-04-28 |
2019-07-12 |
江苏豪森药业集团有限公司 |
沙格列汀包衣片及其制备方法
|
|
CN114786772B
(zh)
|
2019-12-04 |
2024-04-09 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
CA3158184A1
(en)
|
2019-12-04 |
2021-08-10 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
|
ES2973549T3
(es)
|
2019-12-04 |
2024-06-20 |
Albireo Ab |
Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
|
|
CA3158181A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
JP7514121B2
(ja)
*
|
2020-06-23 |
2024-07-10 |
沢井製薬株式会社 |
サキサグリプチン含有製剤及びその製造方法
|
|
EP4188541B1
(en)
|
2020-08-03 |
2024-12-25 |
Albireo AB |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
JP2023549226A
(ja)
|
2020-11-12 |
2023-11-22 |
アルビレオ エービー |
進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
|
|
JP2024500309A
(ja)
|
2020-12-04 |
2024-01-09 |
アルビレオ エービー |
ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
|
|
JP2022135147A
(ja)
*
|
2021-03-04 |
2022-09-15 |
日医工株式会社 |
サキサグリプチン含有錠剤
|
|
TW202313579A
(zh)
|
2021-06-03 |
2023-04-01 |
瑞典商艾爾比瑞歐公司 |
苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
|
|
KR20220165346A
(ko)
|
2021-06-08 |
2022-12-15 |
동아에스티 주식회사 |
에보글립틴의 안정성이 개선된 제제
|